A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients-with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings

作者:Cortes Jorge; Talpaz Moshe; Bixby Dale; Deininger Michael; Shah Neil; Flinn Ian W; Mauro Michael; O'Hare Thomas; Hu Simin; Kan Rebecca; Rivera Victor M; Clackson Tim; Haluska Frank; Kantarjian Hagop
来源:52nd Annual Meeting of the American-Society-of-Hematology (ASH), 2010-12-04 to 2010-12-07.
  • 出版日期2010-11-19